New monthly shot for schizophrenia enters early human testing
Disease control
Not yet recruiting
This study is testing a new long-acting injectable medicine called AX251 in 48 adults with stable schizophrenia. The goal is to see how the drug moves through the body and whether it is safe. Participants receive a single shot and are monitored for side effects and drug levels ov…
Phase: PHASE1 • Sponsor: Anxo Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 12, 2026 13:39 UTC